# A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma

**Status:** Recruiting

## Eligibility Criteria

**Sex:** Male or Female
**Age Group:** Not specified
This study is NOT accepting healthy volunteers

**Inclusion Criteria:**

- at least 12 years old - diagnosis of advanced (metastatic or unresectable primary) pheochromocytoma or paraganglioma - prior treatment with other somatostatin analog, chemotherapy, radiotherapy - at least ambulatory and able to do all self care but unable to carry out any work activities; up and about more than 50% of waking hours - no known medical condition causing an inability to swallow oral medications - see link to clinicaltrials.gov for complete inclusion criteria

**Exclusion Criteria:**

- women who are pregnant or breastfeeding

## Conditions & Interventions

**Interventions:**
Procedure: Biospecimen Collection, Procedure: Computed Tomography with Contrast, Procedure: Magnetic Resonance Imaging, Drug: Olaparib, Other: Quality-of-Life Assessment, Drug: Temozolomide
**Conditions:**
Cancer
**Keywords:**
Neuroendocrine, Paraganglioma, Pheochromocytoma

## More Information

**Description:** This trial studies how well the addition of olaparib to the usual treatment, temozolomide, works in treating patients with neuroendocrine cancer (pheochromocytoma or paraganglioma) that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (unresectable).
**Study Contact:** Stephanie Knutson - stephannie.knutson@fairview.org
**Principal Investigator:** Puneet Cheema
**Phase:** PHASE2
**IRB Number:** MMCORC088